Progress in histone deacetylase inhibitors in non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2016.09.016
- VernacularTitle:组蛋白去乙酰化酶抑制剂在非霍奇金淋巴瘤中的研究进展
- Author:
Ying LI
;
Xin WANG
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Histone deacetylase inhibitor;
Clinical trial
- From:
Journal of Leukemia & Lymphoma
2016;25(9):568-572
- CountryChina
- Language:Chinese
-
Abstract:
Histone deacetylase (HDAC) is a protease which regulates gene expression and modify the structure of chromosome. The balance between acetylation and deacetylation of histone plays an important role in maintaining cellular function and the process of genes expression. Overexpression of HDAC and recruitment by transcription factors inhibit the expression of certain genes, leading to tumorigenesis and other diseases. Recently, with the further research on cancer epigenetics, HDAC inhibitors have increasingly caught attention. As a novel class of antitumor agents, HDAC inhibitors are widely explored in hematological malignancies. There are several kinds of HDAC inhibitors for the treatment and clinical research of non-Hodgkin lymphoma (NHL), such as vorinostat, belinostat, chidamide, CUDC-907. This article mainly describes the development of the HDAC inhibitors in NHL.
